目的:本研究旨在比较最初接受法利单抗或阿柏西普治疗的新生血管性年龄相关性黄斑变性(nAMD)患者的治疗结果。
方法:这项研究纳入了接受法利单抗或阿柏西普连续三个月注射作为负荷阶段的未治疗nAMD患者。在1:1PSM中,性别,年龄,最佳矫正视力(BCVA),黄斑中心厚度(CMT),中央脉络膜厚度(CCT),选择治疗前状态的AMD亚型作为协变量。我们检查了BCVA,CMT,CCT,和剩余的流体在1-,2-,第一次注射后3个月。
结果:PSM后,法利单抗和阿柏西普组各43只眼。两组BCVA均有显著改善,CMT,和CCT在1-,2-,与基线相比,初次注射后3个月。同时,两组在任何时间点的BCVA没有观察到显著差异,CMT,CCT。在1个月,法利单抗组18.6%的患者和阿柏西普组41.9%的患者表现出残余的视网膜下液或视网膜内液,组间差异显著(P=0.03)。
结论:法利单抗和阿柏西普的三次负荷注射后,BCVA有所改善。Faricimab可能在减少日本队列中的视网膜下液方面提供有利的早期治疗反应。
OBJECTIVE: This study aimed to compare the treatment outcomes of patients with neovascular age-related macular degeneration (nAMD) who initially received
faricimab or aflibercept treatment using propensity score matching (PSM) to align patient backgrounds.
METHODS: Patients with treatment-naïve nAMD who received either
faricimab or aflibercept for three consecutive monthly injections as the loading phase were enrolled in this study. In the 1:1 PSM, sex, age, best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and AMD subtypes in the pre-treatment state were selected as covariates. We examined the BCVA, CMT, CCT, and remaining fluid at 1-, 2-, and 3-month after the first injection.
RESULTS: After PSM, 43 eyes were included in the
faricimab and aflibercept group each. Both groups showed significant improvements in BCVA, CMT, and CCT at 1-, 2-, and 3-month after the initial injection compared with baseline. Meanwhile, no significant differences were observed between the two groups at any time point regarding BCVA, CMT, and CCT. At 1-month, 18.6% of patients in the
faricimab group and 41.9% in the aflibercept group demonstrated residual subretinal fluid or intraretinal fluid, with a significant difference between the groups (P = 0.03).
CONCLUSIONS: The BCVA improved after three loading injections of both faricimab and aflibercept.
Faricimab may provide a favorable early treatment response in reducing subretinal fluid in a Japanese cohort.